Phase II Study of Ivonescimab Combined With TROP2 ADC for Treating Brain Metastases in Adults With Triple-Negative Breast Cancer
Led by Fudan University · Updated on 2025-01-27
39
Participants Needed
1
Research Sites
52 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying treatment options for patients with triple-negative breast cancer TNBC that has spread to the brain. This condition is serious, with a poor prognosis and median survival of less than six months. The study aims to explore the effectiveness and safety of combining ivonescimab with TROP2 antibody-drug conjugates such as sacituzumab govitecan in treating these brain metastases. This is a phase II, single-arm, prospective clinical trial focusing on this patient group.
Participants will receive ivonescimab at 20 mgkg intravenously on day 1 every three weeks, combined with sacituzumab govitecan at 10 mgkg intravenously on days 1 and 8 every three weeks. Treatment continues until the disease progresses, intolerable side effects occur, consent is withdrawn, or the investigator decides to stop medication. The study includes patients with untreated brain metastases and those with progression after radiotherapy. Various biological samples will be collected for exploratory molecular analysis.
During the study, participants will undergo brain MRI to confirm metastases and regular assessments to monitor tumor response, including the primary outcome of intracranial objective response rate within about 12 weeks. Secondary outcomes include clinical benefit rate, progression-free survival, and overall survival, with follow-up extending up to approximately 30 months. Safety, laboratory tests, and patients overall health will be closely monitored throughout the trial period.
CONDITIONS
Brief Title
BrAin Metastasis in tripLe Negateive Breast Cancer: IvoneScimab and Trop2 ADC
Research Team
J
Jian Zhang, MD,PhD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Diagnosis of unresectable locally advanced, recurrent, or metastatic triple-negative breast cancer after taxane treatment failure
Availability of ten tissue pathology slides from primary or metastatic lesions for molecular analysis
Brain metastases confirmed by MRI with at least one lesion ≥1.0 cm not previously radiated or showing progression after local treatment
For untreated brain metastases: no prior CNS radiotherapy or at least 2 weeks since craniotomy without radiotherapy
For treated brain metastases: progression or new lesions after whole brain or stereotactic radiotherapy
Stable use of mannitol or hormones for at least one week before enrollment
Adequate blood, liver, and kidney function
Ability to understand study procedures and provide informed consent
You will not qualify if you...
Presence of soft meningeal metastases confirmed by MRI or lumbar puncture
Uncontrolled third-space effusions like large pleural effusion or ascites
Recent whole brain radiotherapy, chemotherapy, or surgery within 2 weeks before study drug treatment; targeted or endocrine therapy within 1 week
Previous use of monoclonal or bispecific antibodies targeting VEGF-A or PD-1/PD-L1/CTLA-4 or prior TROP2 ADC drugs
Participation in other drug trials within 2 weeks before enrollment
Concurrent anti-tumor treatments for other cancers
Other malignant tumors within past 5 years except certain cured skin or thyroid cancers
Severe heart diseases including congestive heart failure NYHA class >2, unstable angina, recent myocardial infarction, significant arrhythmias
Known allergy to study drug components
Uncontrolled serious infections
History of immunodeficiency diseases or organ transplantation; active hepatitis B or C without proper treatment
Use of live attenuated vaccines within 28 days before randomization or planned during study
Active autoimmune diseases except certain controlled conditions
Definite neurological or mental disorders like epilepsy or dementia
Pregnant or breastfeeding women or unwillingness to use contraception
Severe concomitant diseases endangering safety or study completion
Any other conditions judged unsuitable by the investigator
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Treatment
Duration - Up to approximately 30 months
Participants receive Ivonescimab combined with TROP2 ADC administered intravenously every 3 weeks.
Visits every 3 weeks for drug administration
Follow-up
Duration - Up to approximately 30 months
Participants are monitored for survival and disease progression after treatment ends.
Periodic visits during follow-up period
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Similar Trials
Evaluation of 18F-Fluciclovine PET Imaging for Brain Metastasis Response After Stereotactic Radiosurgery
Study of 7T Brain MRI to Detect Small Brain Metastases in Adults With Small-cell Lung Cancer Who Decline Preventive Brain Radiation
Phase II Study of Nivolumab Combined with Ipilimumab and Cabozantinib for Untreated Renal Cell Carcinoma Brain Metastases
Phase II Study of Tucatinib and Ado-trastuzumab Emtansine T-DM1 for HER2-positive Metastatic Solid Tumors with Brain Metastases
Phase 3 Study Comparing ESG401 to Chemotherapy as First Treatment
for Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer
Study on Sparing the Hippocampus During Whole Brain Radiotherapy to Protect Memory in Patients with Brain Metastases
Phase II Study of Datopotamab Deruxtecan, Carboplatin, and Pembrolizumab for Untreated Brain Metastases in Non-Small Cell Lung Cancer
Phase III Study Comparing BL-B01D1 Plus Anti-PD-1 Antibody Versus Nab-paclitaxel Plus Anti-PD-1 Antibody in Women With Previously Untreated Advanced or Metastatic Triple-Negative Breast Cancer
Study of MR001 Drug for Patients Aged 18-75 With Advanced Triple-Negative Breast Cancer That Has Returned or Spread After Previous Treatments
Phase II Study of Stereotactic Radiosurgery for Brain Metastases in Adults with Small Cell Lung Cancer
AK112, a novel PD-1/VEGF bispecific antibody, in combination with chemotherapy in patients with advanced non-small cell lung cancer (NSCLC): an open-label, multicenter, phase II trial.
Final Results From the Randomized Phase III ASCENT Clinical Trial in Metastatic Triple-Negative Breast Cancer and Association of Outcomes by Human Epidermal Growth Factor Receptor 2 and Trophoblast Cell Surface Antigen 2 Expression.